Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

B
B. Bertelsen, Marianne

SP Sundhedsdata, The Data Unit, Capital Region of Denmark
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Marianne B. Bertelsen
Favorite
Bödör, Csaba

Semmelweis University / HCEMM
1163 - Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
Csaba Bödör
Favorite
Bašić-Kinda, Sandra

UHC Zagreb
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Sandra Bašić-Kinda
Favorite
Bachurski, Daniel

Department I for Internal Medicine, University Hospital Cologne
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Daniel Bachurski
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Daniel Bachurski
Favorite
Bachy, Emmanuel

Pierre Bénite
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Emmanuel Bachy
Favorite
Baek, Grace

Fred Hutchinson Cancer Center / UW Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Grace Baek
Favorite
Baeten, Kurt

Janssen
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Kurt Baeten
Favorite
Bai, Longchuan

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Longchuan Bai
Favorite
Bajecny, Martin

Charles University, First Medical Faculty, Institute of Pathological Physiology
1015 - Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Martin Bajecny
Favorite
Bajwa, Naghmana

AstraZeneca
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Naghmana Bajwa
Favorite
Baker, Deborah

CLL Advocates Network
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Deborah Baker
Favorite
Balakrishnan, Mini

Biomea Fusion
2019 - Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models
Mini Balakrishnan
Favorite
Balbas, Minna

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Minna Balbas
Favorite
Baldoni, Stefano

Department of Life, Hematology Section, Health and Environmental Sciences, University of L'Aquila
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Stefano Baldoni
Favorite
Banerji, Versha

University of Manitoba
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Versha Banerji
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Versha Banerji
Favorite
Baran, Andrea

University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Andrea Baran
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Andrea Baran
Favorite
Barbaglio, Federica

IRCCS Ospedale San Raffaele
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Federica Barbaglio
Favorite
Barnea Slonim, Liron

King's College Hospital
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Liron Barnea Slonim
Favorite
Barnes, Gisoo

BeiGene USA, Inc.
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Gisoo Barnes
Favorite
Barnes, Jeffrey

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Jeffrey Barnes
Favorite
Barrientos, Jacqueline

Mount Sinai Comprehensive Cancer Center
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Jacqueline Barrientos
Favorite
1226 - Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience
Jacqueline Barrientos
Favorite
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Jacqueline Barrientos
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Jacqueline Barrientos
Favorite
Barr, Paul

Wilmot Cancer Institute / University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Paul Barr
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Paul Barr
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Paul Barr
Favorite
Basen-Engquista, Karen

The University of Texas MD Anderson Cancer Center
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Karen Basen-Engquista
Favorite
Basic-Kinda, Sandra

University Hospital Centre Zagreb
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Sandra Basic-Kinda
Favorite
Baskar, Sivasubramanian

Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Sivasubramanian Baskar
Favorite
Batth, Gagandeep

Oxford Molecular Diagnostics Centre
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Gagandeep Batth
Favorite
Bauma, Miranda

The University of Texas MD Anderson Cancer Center
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Miranda Bauma
Favorite
Bay, Jacques-Olivier

CHU Clermont-Ferrand
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Jacques-Olivier Bay
Favorite
Beà, Sílvia

Hospital Clínic de Barcelona
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Sílvia Beà
Favorite
Beauvais, David

CHU Lille
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
David Beauvais
Favorite
Behnken, Amy

Division of Hematology, Department of Medicine, Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Amy Behnken
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Amy Behnken
Favorite
Bellia, Matteo

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Matteo Bellia
Favorite
Bello, Celeste

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Celeste Bello
Favorite
Bene, Marie-C

Nantes University, CRCI2NA
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Marie-C Bene
Favorite
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Marie-C Bene
Favorite
Benintende, Giulia

Department of Medicine 5, Haematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsklinikum
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Giulia Benintende
Favorite
Benito Sánchez, Rocío

University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Rocío Benito Sánchez
Favorite
Bennett Caces, Donne

Janssen
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Donne Bennett Caces
Favorite
Bennett, Rory

Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre
1150 - Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)
Rory Bennett
Favorite
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Rory Bennett
Favorite
Benoodt, Lauren

University of Rochester School of Medicine and Dentistry
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Lauren Benoodt
Favorite
Benrashid, Samon

Hematology Oncology Translational Research Laboratory, Levine Cancer Institute/Atrium Health
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Samon Benrashid
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Samon Benrashid
Favorite
Bensaber, Hedi

Centre Hospitalier et Universitaire de Clermont-Ferrand
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Hedi Bensaber
Favorite
Benzel, Julia

AbbVie
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Julia Benzel
Favorite
Berca, Catalina

Institut Pasteur de Montevideo
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Catalina Berca
Favorite
Bergua Burgues, Juan Miguel

Hospital San Pedro de Alcántara
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Juan Miguel Bergua Burgues
Favorite
Bermejo, Laura

Quirónsalud
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Laura Bermejo
Favorite
Bernatowiez, Juliana
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Juliana Bernatowiez
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Juliana Bernatowiez
Favorite
Bernes, Petra

General Hospital Pula
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Petra Bernes
Favorite
Bernstein, Melanie

Weill Cornell Medicine
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Melanie Bernstein
Favorite
Berrahouane, Rayane

Hématologie Clinique, CHU Montpellier
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Rayane Berrahouane
Favorite
Bertini, Martín

Hospital Alvarez
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Martín Bertini
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Martín Bertini
Favorite
Bertoni, Fransesco

Institute of Oncology Research, Faculty of Biomedical Sciences, USI
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Fransesco Bertoni
Favorite
Beutner, Dirk
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Dirk Beutner
Favorite
Bezares, Fernando R

Sección de Hematología, Hospital General de Agudos Dr. Teodoro Álvarez
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Fernando R Bezares
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Fernando R Bezares
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Fernando R Bezares
Favorite
Bhat, Seema

The Ohio State University Comprehensive Cancer Center
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Seema Bhat
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Seema Bhat
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Seema Bhat
Favorite
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Seema Bhat
Favorite
Bhuiya, Sabreen

The Feinstein Institutes for Medical Research, Northwell Health
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Sabreen Bhuiya
Favorite
Bian, Yuanyuan Faith

Eli Lilly and Company
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Yuanyuan Faith Bian
Favorite
Biondo, Juliana

Genentech
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Juliana Biondo
Favorite
Bishop, Cynthia

Guy's Hospital
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Cynthia Bishop
Favorite
Bittolo, Tamara

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Tamara Bittolo
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Tamara Bittolo
Favorite
Blachly, James

Division of Hematology, Department of Internal Medicine, The Ohio State University James Cancer Hospital
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
James Blachly
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
James Blachly
Favorite
Blakemore, Stuart James

CECAD
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Stuart James Blakemore
Favorite
Blanco Ares, Gonzalo

Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Gonzalo Blanco Ares
Favorite
Blaser, Bradley
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Bradley Blaser
Favorite
Bley, Nadine
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Nadine Bley
Favorite
Bliven, Sean Patrick

University of Alabama at Birmingham
1148 - Time to treatment initiation in 17p-deleted Chronic Lymphocytic Leukemia has no influence on overall survival
Sean Patrick Bliven
Favorite
Bloehdorn, Johannes

Department III of Internal Medicine, Ulm University
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Johannes Bloehdorn
Favorite
blombery, Piers

Peter MacCallum Cancer Centre
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Piers blombery
Favorite
Bloom, Paige

Wilmot Cancer Institute / University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Paige Bloom
Favorite
Blyth, Emily

The Westmead Institute for Medical Research, Westmead Hospital, Sydney Cellular Therapies Laboratory
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Emily Blyth
Favorite
Boccellato, Elia

1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Elia Boccellato
Favorite
Bohn, Jan-Paul

Department of Internal Medicine V, Medical University Innsbruck
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Jan-Paul Bohn
Favorite
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Jan-Paul Bohn
Favorite
Bohunova, Michaela

1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
4004 - Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients
Michaela Bohunova
Favorite
Bombaci, Felice

CLL Advocates Network
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Felice Bombaci
Favorite
Bomben, Riccardo

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Riccardo Bomben
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Riccardo Bomben
Favorite
Bonato, Alice

International Centre for Genetic Engineering and Biotechnology
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Alice Bonato
Favorite
Bond, David

The Ohio State University
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
David Bond
Favorite
Bordini, Jessica

IRCCS Ospedale San Raffaele
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Jessica Bordini
Favorite
Borge, Mercedes

IMEX-CONICET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Mercedes Borge
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Mercedes Borge
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Mercedes Borge
Favorite
Bosch, Francesc

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Francesc Bosch
Favorite
Boubaya, Marouane

Département de Recherche Clinique, Hôpital Avicenne, APHP
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Marouane Boubaya
Favorite
Boucher, Rebecca

Cancer Research UK Clinical Trials Unit, University of Birmingham
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Rebecca Boucher
Favorite
Bousquet, Hugo
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Hugo Bousquet
Favorite
Boyer, Michelle

Genentech Inc
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Michelle Boyer
Favorite
Bozek, Katarzyna

Center for Molecular Medicine Cologne CMMC, University of Cologne
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Katarzyna Bozek
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Katarzyna Bozek
Favorite
Bradley, Jennie

IQVIA
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Jennie Bradley
Favorite
Braggio, Esteban

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Esteban Braggio
Favorite
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Esteban Braggio
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Esteban Braggio
Favorite
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Esteban Braggio
Favorite
Brander, Danielle

Duke University Medical Center
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Danielle Brander
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Danielle Brander
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Danielle Brander
Favorite
Brathaban, Nivetha
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Nivetha Brathaban
Favorite
Bravetti, Clotilde
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Clotilde Bravetti
Favorite
Bravo, Brandon
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Brandon Bravo
Favorite
Breen, William

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
William Breen
Favorite
Breitmeyer, James

Oncternal Therapeutics
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
James Breitmeyer
Favorite
Bridge, Helen

AstraZeneca
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Helen Bridge
Favorite
Brieghel, Christian

Department of Hematology, Copenhagen University Hospital Rigshospitalet
1101 - Association between hypertension and overall survival in chronic lymphocytic leukemia
Christian Brieghel
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Christian Brieghel
Favorite
Brinkmann, Berit J.

University of Heidelberg
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Berit J. Brinkmann
Favorite
Brion, Annie
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Annie Brion
Favorite
Brodersen, Andrea

Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Andrea Brodersen
Favorite
Bron, Dominique

Department of hematology, Jules Bordet Institute
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Dominique Bron
Favorite
Brown, Jennifer

Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI); Department of Medicine, Harvard Medical School (HMS)
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Jennifer Brown
Favorite
1031 - Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Jennifer Brown
Favorite
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Jennifer Brown
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Jennifer Brown
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Jennifer Brown
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Jennifer Brown
Favorite
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Jennifer Brown
Favorite
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Jennifer Brown
Favorite
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Jennifer Brown
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Jennifer Brown
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Jennifer Brown
Favorite
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Jennifer Brown
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Jennifer Brown
Favorite
Bruch, Peter-Martin

University of Heidelberg
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Peter-Martin Bruch
Favorite
Brunner, Andrea
1011 - In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations
Andrea Brunner
Favorite
Bruno, Jennifer

University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Jennifer Bruno
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Jennifer Bruno
Favorite
Bruscaggin, Alessio

Institute of Oncology Research
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Alessio Bruscaggin
Favorite
Brychtova, Yvona

Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Yvona Brychtova
Favorite
Bubik, Rachel

Department of Pharmacy, Mayo Clinic
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Rachel Bubik
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Rachel Bubik
Favorite
Buckley, Paul

King's College London
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Paul Buckley
Favorite
Budisavljevic, Ivana

UHC Rijeka
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Ivana Budisavljevic
Favorite
Bulj, Nikola

University Hospital Centre Sisters of Mercy and Medical School, University of Zagreb
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Nikola Bulj
Favorite
Buonincontro, Brenda
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Brenda Buonincontro
Favorite
Burcoveanu, Cristina

Clinic of Haematology, Regional Institute of Oncology Iasi
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Cristina Burcoveanu
Favorite
Burke, John M.

Rocky Mountain Cancer Centers, US Oncology Research
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
John M. Burke
Favorite
Burley, Thomas

Brighton and Sussex Medical School
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Thomas Burley
Favorite
Burton, Elizabeth

MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Elizabeth Burton
Favorite
busca, Alessandro

A.O.U. Città della Salute e della Scienza di Torino
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Alessandro busca
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Alessandro busca
Favorite
Butcher, Belinda

Australasian Leukemia and Lymphoma Group
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Belinda Butcher
Favorite
Butler, Thomas

Biomea Fusion
2019 - Covalent menin inhibitor, BMF-219, impacts key gene signatures and molecular pathways in Chronic Lymphocytic Leukemia patient-derived models
Thomas Butler
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Thomas Butler
Favorite
By, Kunthel

BeiGene USA
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Kunthel By
Favorite
Byrd, John

University of Cincinnati College of Medicine
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
John Byrd
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
John Byrd
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
John Byrd
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
John Byrd
Favorite